Widespread morbilliform rash due to sorafenib or vemurafenib treatment for advanced cancer; experience of a tertiary dermato-oncology clinic-Reference-Cited by-同舟云学术

Widespread morbilliform rash due to sorafenib or vemurafenib treatment for advanced cancer; experience of a tertiary dermato-oncology clinic

Published:2016-01-29 Issue:4 Volume:55 Page:473-478
ISSN:0011-9059
Container-title:International Journal of Dermatology
language:en
Short-container-title:Int J Dermatol

Author:

Ollech Ayelet¹,Stemmer Salomon M.²³,Merims Sharon⁴,Lotem Michal⁴,Popovtzer Aron²³,Hendler Daniel²³,Hodak Emmilia¹³,Didkovsky Elena⁵,Amitay-Laish Iris¹³

Affiliation:

1. Department of Dermatology; Rabin Medical Center; Petach Tikva Israel

2. Institute of Oncology; Davidoff Center; Rabin Medical Center; Petach Tikva Israel

3. Sackler Faculty of Medicine; Tel Aviv University; Tel Aviv Israel

4. Center for Melanoma and Cancer Immunotherapy; Sharett Institute of Oncology; Hadassah Hebrew University Medical Center; Jerusalem Israel

5. Department of Pathology; Rabin Medical Center; Petach Tikva Israel

Publisher

Wiley

Subject

Dermatology

Reference21 articles.

1. Angiogenesis;Wilhelm;Cancer Res,2004

2. Sorafenib in advanced clear-cell renal-cell carcinoma;Escudier;N Engl J Med,2007

3. Sorafenib in advanced hepatocellular carcinoma;Llovet;N Engl J Med,2008

4. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomized, double-blind, phase 3 trial;Brose;Lancet,2014

5. Dermatologic symptoms associated with the multikinase inhibitor sorafenib;Robert;J Am Acad Dermatol,2009

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Epidermal necrolysis in the context of immuno‐oncologic medication as well as kinase inhibitors and biologics;JDDG: Journal der Deutschen Dermatologischen Gesellschaft;2022-06

2. Epidermale Nekrolyse im Zusammenhang mit immunonkologischen Medikamenten, Kinaseinhibitoren sowie Biologika;JDDG: Journal der Deutschen Dermatologischen Gesellschaft;2022-06

3. A first‐in‐class, first‐in‐human, phase I trial of CIGB ‐552, a synthetic peptide targeting COMMD1 to inhibit the oncogenic activity of NF‐κB in patients with advanced solid tumors;International Journal of Cancer;2021-05-27

4. Potentially life‑threatening severe cutaneous adverse reactions associated with tyrosine kinase inhibitors (Review);Oncology Reports;2020-12-24

5. Dermatological Toxicities of Bruton’s Tyrosine Kinase Inhibitors;American Journal of Clinical Dermatology;2020-07-01